Published in J Neurosci on November 02, 2005
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A (2008) 2.27
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation (2008) 2.03
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J (2007) 1.97
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat (2009) 1.69
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. Brain (2016) 1.41
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol (2008) 1.38
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.37
Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.37
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A (2013) 1.24
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Candidate drug targets for prevention or modification of epilepsy. Annu Rev Pharmacol Toxicol (2014) 1.15
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J Clin Invest (2014) 1.15
Divergent effects of prostaglandin receptor signaling on neuronal survival. Neurosci Lett (2007) 1.14
Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J Neurosci (2013) 1.14
Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol (2014) 1.14
Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem (2008) 1.14
Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A (2010) 1.13
Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci (2013) 1.11
Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol (2010) 1.09
Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A (2012) 1.06
Transcriptome analysis of monocyte-HIV interactions. Retrovirology (2010) 0.98
Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection. J Neurosci (2011) 0.98
Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol Aging (2010) 0.97
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96
Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? J Neuroimmune Pharmacol (2011) 0.94
Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2. Am J Pathol (2009) 0.94
Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp Neurol (2009) 0.92
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem (2012) 0.91
Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity. Neurotoxicology (2011) 0.91
Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am J Pathol (2009) 0.90
Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci (2014) 0.90
Prostaglandin signalling in cerebral ischaemia. Br J Pharmacol (2010) 0.89
Lead optimization studies of cinnamic amide EP2 antagonists. J Med Chem (2014) 0.88
Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery. ASN Neuro (2015) 0.87
Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor. J Biol Chem (2009) 0.87
Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease. Alzheimers Dement (2007) 0.86
Prostanoid receptor EP2 as a therapeutic target. J Med Chem (2013) 0.86
Eryptosis as a marker of Parkinson's disease. Aging (Albany NY) (2014) 0.86
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid β neurotoxicity in vitro. J Neuroimmune Pharmacol (2012) 0.85
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol (2014) 0.85
Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease. Exp Neurol (2009) 0.84
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol Dis (2015) 0.84
DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. Am J Pathol (2009) 0.84
Development of second generation EP2 antagonists with high selectivity. Eur J Med Chem (2014) 0.83
Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain. Biochim Biophys Acta (2016) 0.82
Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus. Neuropharmacology (2015) 0.82
The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases. Front Cell Neurosci (2014) 0.81
Purinergic signaling induces cyclooxygenase-1-dependent prostanoid synthesis in microglia: roles in the outcome of excitotoxic brain injury. PLoS One (2011) 0.81
Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Exp Mol Pathol (2013) 0.80
Select cyclopentenone prostaglandins trigger glutathione efflux and the role of ABCG2 transport. Free Radic Biol Med (2009) 0.79
Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism. Br J Pharmacol (2012) 0.78
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease. Curr Immunol Rev (2015) 0.78
Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. Sci Rep (2015) 0.77
Dietary repletion with ω3 fatty acid or with COX inhibition reverses cognitive effects in F3 ω3 fatty-acid-deficient mice. Comp Med (2014) 0.77
MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.77
Cerebroprotection by the neuronal PGE2 receptor EP2 after intracerebral hemorrhage in middle-aged mice. J Cereb Blood Flow Metab (2016) 0.77
Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells. PLoS One (2016) 0.76
Autophagy deficient keratinocytes display increased DNA damage, senescence and aberrant lipid composition after oxidative stress in vitro and in vivo. Redox Biol (2016) 0.75
PGE2-EP3 signaling pathway contributes to protective effects of misoprostol on cerebral injury in APP/PS1 mice. Oncotarget (2016) 0.75
Anti-Inflammatory and Neuroprotective Effects of PGE2 EP4 Signaling in Models of Parkinson's Disease. J Neuroimmune Pharmacol (2016) 0.75
Multi-targeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases. J Med Chem (2017) 0.75
Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2. Expert Opin Ther Pat (2015) 0.75
Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease. ACS Chem Neurosci (2016) 0.75
Inhibition of STAT3- and MAPK-dependent PGE2 synthesis ameliorates phagocytosis of fibrillar β-amyloid peptide (1-42) via EP2 receptor in EMF-stimulated N9 microglial cells. J Neuroinflammation (2016) 0.75
Microarray analysis of the in vivo response of microglia to Aβ peptides in mice with conditional deletion of the prostaglandin EP2 receptor. Genom Data (2015) 0.75
Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. Pharmaceuticals (Basel) (2010) 0.75
Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats. Curr Alzheimer Res (2016) 0.75
Relationship Between Obesity, Alzheimer's Disease, and Parkinson's Disease: an Astrocentric View. Mol Neurobiol (2016) 0.75
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Ballistic carbon nanotube field-effect transistors. Nature (2003) 4.35
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther (2004) 3.40
Fluorescence visualization of newly synthesized proteins in mammalian cells. Angew Chem Int Ed Engl (2006) 2.96
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Severe fever with thrombocytopenia syndrome virus, Shandong Province, China. Emerg Infect Dis (2012) 2.77
Polarization-controlled tunable directional coupling of surface plasmon polaritons. Science (2013) 2.73
Improvement of Fat Graft Survival with Autologous Bone Marrow Aspirate and Bone Marrow Concentrate: A One-Step Method. Plast Reconstr Surg (2016) 2.59
A fluorogenic 1,3-dipolar cycloaddition reaction of 3-azidocoumarins and acetylenes. Org Lett (2004) 2.57
A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol (2009) 2.53
Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation (2006) 2.50
Cilium-generated signaling and cilia-related disorders. Lab Invest (2005) 2.42
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci (2004) 2.40
Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med (2012) 2.38
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol (2003) 2.22
GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data. Bioinformatics (2012) 2.21
Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol (2009) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
High-kappa dielectrics for advanced carbon-nanotube transistors and logic gates. Nat Mater (2002) 2.18
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Modeling elastic properties in finite-element analysis: how much precision is needed to produce an accurate model? Anat Rec A Discov Mol Cell Evol Biol (2005) 2.01
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99
An investigation of the mechanisms of electronic sensing of protein adsorption on carbon nanotube devices. J Am Chem Soc (2004) 1.98
Effect of oral ALA supplementation on oxidative stress and insulin sensitivity among overweight/obese adults: a double-blinded, randomized, controlled, cross-over intervention trial. Int J Cardiol (2012) 1.98
OPTICAL COHERENCE TOMOGRAPHIC ANGIOGRAPHY IN CENTRAL SEROUS CHORIORETINOPATHY. Retina (2016) 1.93
Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell (2007) 1.90
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res (2010) 1.89
Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myo1c. Dev Cell (2007) 1.88
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Electron transport in very clean, as-grown suspended carbon nanotubes. Nat Mater (2005) 1.86
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med (2005) 1.85
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Selective dye-labeling of newly synthesized proteins in bacterial cells. J Am Chem Soc (2005) 1.77
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Cilia and flagella revealed: from flagellar assembly in Chlamydomonas to human obesity disorders. Cell (2004) 1.76
Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol (2009) 1.76
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
ABSORB: Atlas Building by Self-organized Registration and Bundling. Neuroimage (2010) 1.75
An aurora kinase is essential for flagellar disassembly in Chlamydomonas. Dev Cell (2004) 1.75
Thermal conductance of an individual single-wall carbon nanotube above room temperature. Nano Lett (2006) 1.73
LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.72
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood (2010) 1.72
Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol (2009) 1.71
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res (2009) 1.70
High-field quasiballistic transport in short carbon nanotubes. Phys Rev Lett (2004) 1.68
The feeding biomechanics and dietary ecology of Australopithecus africanus. Proc Natl Acad Sci U S A (2009) 1.66
A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 1.64
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Self-directed self-assembly of nanoparticle/copolymer mixtures. Nature (2005) 1.62
Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res (2013) 1.61
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med (2008) 1.61
The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest (2002) 1.56
The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol (2012) 1.56
Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol (2005) 1.55
Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol (2011) 1.54
Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology (2005) 1.53
A novel Crumbs3 isoform regulates cell division and ciliogenesis via importin beta interactions. J Cell Biol (2007) 1.53
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol (2008) 1.52
Hydrogen-rich saline reduces the oxidative stress and relieves the severity of trauma-induced acute pancreatitis in rats. J Trauma Acute Care Surg (2012) 1.50
Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis (2006) 1.49
The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem (2010) 1.48
An experimental design to study adipocyte stem cells for reconstruction of calvarial defects. J Craniofac Surg (2009) 1.47
Genome-scale transcriptome analysis of the desert poplar, Populus euphratica. Tree Physiol (2011) 1.47
Prioritizing risk pathways: a novel association approach to searching for disease pathways fusing SNPs and pathways. Bioinformatics (2008) 1.46
A cone-beam computed tomography study of maxillary first permanent molar root and canal morphology in a Chinese population. J Endod (2010) 1.45
Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest (2007) 1.45
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem (2002) 1.44
Surface modification of tobacco mosaic virus with "click" chemistry. Chembiochem (2008) 1.43
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol (2006) 1.42
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia (2005) 1.42
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42